It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Nasdaq Buoyed by Biotech
The Nasdaq rose 5 points on Monday, due in part to recent happenings in the biopharmaceutical sector.
